Volume : 10, Issue : 12, December – 2023
Title:
METABOLIC ASSOCIATED FATTY LIVER DISEASE (NON-ALCOHOLIC FATTY LIVER DISEASE) AMONG PATIENTS WITH TYPE 2 DIABETES IN SAUDI ARABIA: SYSTEMATIC REVIEW AND META ANALYSIS
Authors :
Dr Maryam Salman Alsharif , Dr saleh saad Alawani , Dr Amer Hassan Alshehri
Abstract :
Background: Non-alcoholic fatty liver disease (NAFLD) is common among patients with type 2 diabetes. However, it is often ignored. When co-exist they exacerbate each other serious consequences. No meta-analysis has assessed NAFLD among patients with diabetes in Saudi Arabia. We aimed to investigate the prevalence and predictors of non-alcoholic fatty liver disease among patients with type 2 diabetes in Saudi Arabia.
Methods: three databases were searched (PubMed, MEDLINE, Cochrane Library, and Web of Science for articles published in English from the first published article up to March 2023. The following terms were used: type 2 diabetes, non-alcoholic fatty liver disease, metabolic associated fatty liver disease, predictors, alanine aminotransferase (ALT), aspartate aminotransferase (AST), Saudi Arabia, and using the protean “AND”and “OR”.
Results: There were 1139 patients from three cross-sectional studies, ALT was higher among patients with NAFLD, odd ratio, 3.30, 95% CI, 3.12-3.49, P-value <0.001, and the Chi-square was1.07. No differences were evident between patients with and without NAFLD regarding AST, odd ratio, -0.00, 95% CI, -5.86-5.86, P-value, 1.0, and the Chi-square was18.03, and HDL, odd ratio, -0.53, 95% CI, -1.21-0.15, P-value, 0.12, and the Chi-square was77.28. NAFLD prevalence was (40% to 80.8.Conclusion: Non-alcoholic fatty liver disease was prevalent among patients with type 2 diabetes in Saudi Arabia and is associated with high ALT, while, high-density lipoproteins and AST were not. Healthcare and treating physicians might need to screen patients with type 2 diabetes for NAFLD. Further larger studies assessing the bone mineral density at different sites are needed.
Keywords: type 2 diabetes, non-alcoholic fatty liver disease, Saudi Arabia.
Cite This Article:
Please cite this article in press Maryam Salman Alsharif et al., Metabolic Associated Fatty Liver Disease (Non-Alcoholic Fatty Liver Disease) Among Patients With Type 2 Diabetes In Saudi Arabia: Systematic Review And Meta Analysis, Indo Am. J. P. Sci, 2023; 10 (12).
Number of Downloads : 10
References:
1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119.
2. Mirghani HO. Distress and psychopathology among Sudanese patients with type 2 diabetes mellitus and its relation to glycaemic control. J Taibah Univ
Med Sci. 2017 Apr 5;12(4):298-303. doi: 10.1016/j.jtumed.2017.02.007.
3. Targher G. Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus? Hepatobiliary Surg Nutr. 2020 Apr;9(2):239-241. doi: 10.21037/hbsn.2019.10.21.
4. Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, CortezPinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H,
Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):60-78. doi: 10.1038/s41575-021-00523-4.
5. Al Humayed SM, Sabaani AAA, Mahfouz AA, Awadalla NJ, Musa MJ, Patel A. Clinical and Biochemical Predictors of Nonalcoholic Fatty Liver Disease among Type 2 Diabetes Mellitus Patients at Primary Health Care Level in South Western Saudi Arabia. Diagnostics (Basel). 2020 Oct 12;10(10):809. doi: 10.3390/diagnostics10100809. NAFLD 174/237.
6. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019 Oct;71(4):793-801. doi: 10.1016/j.jhep.2019.06.021.
7. Sanai FM, Al Khathlan A, Al Fadhli A, Jazzar AS, Hashim AM, Mansour E, Abaalkhail F, Hasan F, Al Mudaiheem H, Al Quraishi H, Bottomley J, Alswat KA, Al Ghamdi M, Farghaly M, Fathy M, Awad N, Mohamed O, Kozma S, AlHamoudi W, Al-Jedai A. Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates, and Kuwait. Hepatol Int. 2021 Aug;15(4):912-921. doi: 10.1007/s12072-021-10182-x.
8. Alswat K, Sanai FM, Al-Hamoudi W, Ismail M, Dahlan Y, AlGhamdi HS, Altraif I, Alalwan A, Babatin MMA, Alqahtani SA. Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry. Diabetes Metab Syndr Obes. 2021 Mar 16;14:1167-1175. doi: 10.2147/DMSO.S300051.
9. Kumar J, Memon RS, Shahid I, Rizwan T, Zaman M, Menezes RG, Kumar S, Siddiqi TJ, Usman MS.. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. Dig Liver Dis. 2021 Jan;53(1):44-51. doi: 10.1016/j.dld.2020.08.021.
10. Zafar Y, Rashid AM, Siddiqi AK, Ellahi A, Ahmed A, Hussain HU, Ahmed F, Menezes RG, Siddiqi TJ, Maniya MT. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2022 Aug-Sep;46(7):101970. doi: 10.1016/j.clinre.2022.101970.
11. Yilmaz Y. Review article: non-alcoholic fatty liver disease and osteoporosis-clinical and molecular crosstalk. Aliment Pharmacol Ther. 2012 Aug;36(4):345 -52. doi: 10.1111/j.1365-2036.2012.05196.x.
12. Alamri AS, Alhomrani M, Alsanie WF, Alghamdi AJ, Alghamdi ZM, AlSubaie AA, Alharthi YA, Alqurashi HH, Asdaq SMB. Prevalence and predictors of non-alcoholic fatty liver disease in tertiary care hospital of Taif, Saudi Arabia: A retrospective study. Saudi J Biol Sci. 2021 Sep;28(9):49214925. doi: 10.1016/j.sjbs.2021.05.063.
13. Alsabaani AA, Mahfouz AA, Awadalla NJ, Musa MJ, Al Humayed SM. NonAlcoholic Fatty Liver Disease among Type-2 Diabetes Mellitus Patients in Abha City, South Western Saudi Arabia. Int J Environ Res Public Health. 2018 Nov 11;15(11):2521. doi: 10.3390/ijerph15112521.
14. Alfadda AA, Sherbeeni SM, Alqutub AN, Aldosary AS, Aldaghri NM, Taylor-
Robinson SD, et al. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the
CORDIAL cohort study. Saudi J Gastroenterol. 2022 May 23. doi:
10.4103/sjg.sjg_73_22.
15. Al Humayed SM, Sabaani AAA, Mahfouz AA, Awadalla NJ, Musa MJ, Patel A. Clinical and Biochemical Predictors of Nonalcoholic Fatty Liver Disease among Type 2 Diabetes Mellitus Patients at Primary Health Care Level in South Western Saudi Arabia. Diagnostics (Basel). 2020 Oct 12;10(10):809. doi:
10.3390/diagnostics10100809.
16. Ajabnoor GMA, Bahijri SM, Enani SM, Alsheikh L, Ahmed M, Alhozali A, AlShali K, Eldakhakhny BM, Alamoudi AA, Al-Ahmadi J, Borai A, Al-Mowallad AS, Tuomilehto J. Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia. Diseases. 2023 Jan 15;11(1):10. doi:
10.3390/diseases11010010.
17. Mohamed AM, Isa HM, Ali MS, Dadi A, Kadhim Z. Prevalence of Nonalcoholic Fatty Liver Disease among Patients with Diabetes Mellitus Attending Primary Health Care Centers in Bahrain. Oman Med J. 2022 Mar
22;37(2):e350. doi: 10.5001/omj.2022.53.
18. Labenz C, Kostev K, Alqahtani SA, Galle PR, Schattenberg JM. Impact of NonAlcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus. Exp Clin Endocrinol Diabetes. 2022 Mar;130(3):172-177. doi:
10.1055/a-1378-4679.
19. Targher G. Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus? Hepatobiliary Surg Nutr. 2020 Apr;9(2):239-241. doi: 10.21037/hbsn.2019.10.21.
20. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431.
21. Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of populationbased observational studies. PLoS Med. 2020 Apr 30;17(4):e1003100. doi:
10.1371/journal.pmed.1003100
22. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019 Oct;71(4):793-801. doi: 10.1016/j.jhep.2019.06.021.
23. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007;30:1212-8. 10.2337/dc06-2247
24. Bril F. Nonalcoholic fatty liver disease in type 2 diabetes: awareness is the first step toward change. Hepatobiliary Surg Nutr. 2020 Aug;9(4):493-496. doi:
10.21037/hbsn.2019.11.11.
25. Mandal A, Bhattarai B, Kafle P, Khalid M, Jonnadula SK, Lamicchane J, Kanth R, Gayam V. Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease. Cureus. 2018 Nov 23;10(11):e3626. doi: 10.7759/cureus.3626.
26. Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG,Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of fatal and non -fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021 Nov;6(11):903-913. doi: 10.1016/S24681253(21)00308-3.
27. Mantovani A, Lonardo A, Vinco G, Zoppini G, Lippi G, Bonora E, Loomba R, Tilg H, Byrne CD, Fabbri L, Targher G. Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis. Diabetes Metab. 2019 Dec;45(6):536-544. doi: 10.1016/j.diabet.2019.04.008.
28. Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022 Jan;71(1):156-162. doi: 10.1136/gutjnl-2020-323082.
29. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) ; European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-402. 10.1016/j.jhep.2015.11.004
30. Italian Association for the Study of the Liver (AISF) AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. Dig Liver Dis 2017;49:471-83. 10.1016/j.dld.2017.01.147
31. Glen J, Floros L, Day C, et al. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. BMJ 2016;354:i4428. 10.1136/bmj.i4428
32. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-57.
10.1002/hep.29367
33. Xie R, Liu M. Relationship Between Non-Alcoholic Fatty Liver Disease and Degree of Hepatic Steatosis and Bone Mineral Density. Front Endocrinol (Lausanne). 2022 Mar 14;13:857110. doi: 10.3389/fendo.2022.857110.